Appendix Table 1. Demographic and Clinical Characteristics of Medicare Fee-for-service Beneficiaries 65 and Older in the
Dartmouth 2003-2007 End-of-life cohort, by Academic Medical Center*
Measure
Low intensity
(N=1,472)
High intensity
(N=1,480)
P-value
Age category
ns
Age 65-69
133 (9.0)
136 (9.2)
Age 70-74
218 (14.8)
248 (16.8)
Age 75-79
308 (20.9)
271 (18.3)
Age 80-84
305 (20.7)
302 (20.4)
Age 85+
508 (34.5)
523 (35.3)
Female sex, %
735 (49.9)
714 (48.2)
ns
Black race, %
141 (9.6)
110 (7.4)
<.05
End-of-life Diagnosis Category, %
ns
Malignant cancer/leukemia
539 (36.6)
532 (35.9)
Chronic pulmonary disease
158 (10.7)
159 (10.7)
Coronary artery disease
103 (7.0)
101 (6.8)
Congestive heart failure
358 (24.3)
365 (24.7)
Peripheral vascular disease
37 (2.5)
32 (2.2)
Severe chronic liver disease
37 (2.5)
44 (3.0)
Diabetes with end organ damage
< 11 (<1)
13 (0.9)
Chronic renal failure
127 (8.6)
125 (8.5)
Dementia
109 (7.4)
109 (7.4)
<11 (<1)
16 (1.1)
n/a
784 (53.3)
1276 (86.2)
< 0.0001
Solid organ transplant, %
Any ICU admission in last 2 years of life, %
*The Dartmouth end of life cohort is the same cohort that was used to identify terminal ICU admissions in order to calculate lifesustaining treatment use in Table 1, bottom half. Performed by special request using MedPAR claims/Dartmouth Atlas (Jonathan
Skinner, May 4 2012)
Appendix Table 2. Demographic and Clinical Characteristics of Medicare Fee-for-service Beneficiaries 65 and Older in the
Dartmouth 2003-2007 End-of-life Cohort with >1 ICU Admission in the Last 2 Years of Life, by Academic Medical Center*
Measure
Low intensity
(N=784)
High intensity
(N=1,276)
Age category
P-value
<0.05
Age 65-69
81 (10.3)
118 (9.3)
Age 70-74
129 (16.5)
203 (15.9)
Age 75-79
183 (23.3)
230 (18.0)
Age 80-84
153 (19.5)
265 (20.8)
Age 85+
238 (30.4)
460 (36.1)
Female sex, %
379 (48.3)
609 (47.7)
ns
77 (9.8)
99 (7.8)
<0.05
Black race, %
End-of-life Diagnosis Category, %
<0.05
Malignant cancer/leukemia
240 (30.6)
405 (31.6)
Chronic pulmonary disease
93 (11.9)
144 (11.3)
Coronary artery disease
53 (6.8)
91 (7.1)
Congestive heart failure
224 (28.6)
355 (27.8)
Peripheral vascular disease
23 (2.9)
28 (2.2)
Severe chronic liver disease
20 (2.6)
38 (3.0)
Diabetes with end organ damage
< 11 (<1)
12 (0.9)
Chronic renal failure
91 (11.6)
118 (9.3)
37 (4.7)
85 (6.7)
<11 (<1)
16 (1.1)
Dementia
Solid organ transplant, %
*The Dartmouth end of life cohort is the same cohort that was used to identify terminal ICU admissions in order to calculate lifesustaining treatment use in Table 1, bottom half. Performed by special request using MedPAR claims/Dartmouth Atlas (Jonathan
Skinner, May 4 2012)
n/a